SPRUCE BIOSCIENCES, INC.
No SEC Form 4 filings for $SPRB in the last 30 days.
See all $SPRB insider activity →SPRUCE BIOSCIENCES, INC. (SPRB) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 sprb-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Spruce Biosciences Reports Second Quarter 2026 Financial Results and Provides Corporate Updates Biologics License Application (BLA) for TA-ERT for the Treatment of MPS IIIB Anticipated in the Fourth Quarter of 2026 TrAnsform
SPRUCE BIOSCIENCES, INC. (SPRB) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. 8-K false 0001683553 0001683553 2026-07-27 2026-07-27 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 27,
Wall Street analysts issued multiple rating changes. JPMorgan raised American Express (AXP) to Overweight, PT $400. Truist upgraded Biogen (BIIB) to Buy, PT $235, citing upcoming Phase 2 and Phase 3 readouts. JPMorgan also raised Keysight (KEYS) to Overweight, PT $400. Other actions included upgrades for Humana (HUM) and downgrades for Papa John’s (PZZA) and Best Buy (BBY).
Over the past 7 days, alphai's AI scored 1 news story mentioning SPRB (SPRUCE BIOSCIENCES, INC.). Coverage has skewed bullish: 1 bullish, 0 neutral, and 0 bearish.
Recent SPRB coverage spans financial news, earnings and corporate actions.
Near-term catalysts center on TA-ERT regulatory path (BLA submission and confirmatory study start) plus cash runway updates.
Board and CMO leadership change can affect clinical/medical strategy execution, but the filing provides no new clinical or financial metrics.
The initiation frames a valuation asymmetry around Priority Review Voucher economics, which can attract value-oriented trading interest.
Analyst target cut may pressure near-term sentiment, but the stock still carries a Buy rating and multiple other firms remain constructive.
Spruce Biosciences (SPRB) shows signs of strong momentum based on recent developments and market sentiment, making it a candidate for short-term trading strategies.
alphai scores every news story that mentions SPRB with an AI model for sentiment and relevance, and aggregates insider trades from SPRUCE BIOSCIENCES, INC.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
SPRUCE BIOSCIENCES, INC. (SPRB) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 sprb-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Spruce Biosciences Reports Second Quarter 2026 Financial Results and Provides Corporate Updates Biologics License Application (BLA) for TA-ERT for the Treatment of MPS IIIB Anticipated in the Fourth Quarter of 2026 TrAnsform
6 min readSPRUCE BIOSCIENCES, INC. (SPRB) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. 8-K false 0001683553 0001683553 2026-07-27 2026-07-27 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 27,
2 min readWall Street analysts issued multiple rating changes. JPMorgan raised American Express (AXP) to Overweight, PT $400. Truist upgraded Biogen (BIIB) to Buy, PT $235, citing upcoming Phase 2 and Phase 3 readouts. JPMorgan also raised Keysight (KEYS) to Overweight, PT $400. Other actions included upgrades for Humana (HUM) and downgrades for Papa John’s (PZZA) and Best Buy (BBY).
4 min readHC Wainwright cut its price target for Spruce Biosciences (NASDAQ:SPRB) from $200 to $150 and kept a “buy” rating, according to a Monday research note cited by Benzinga. The target implies 192.57% upside versus the prior close. Other analysts cited include Oppenheimer “outperform” and Citizens JMP reducing its target to $150. Spruce reported ($8.94) EPS for the quarter on May 13, missing consensus ($7.93).
4 min readDoes Spruce Biosciences, Inc. (SPRB) have what it takes to be a top stock pick for momentum investors? Let's find out.
3 min readSpruce Biosciences Inc. ( NASDAQ:SPRB ) jumped to $175.00 during after-hours trading on Monday, up 34.20% or $44.60 from its closing price. Check out the current price of SPRB stock here. During regular trading hours, SPRB soared $121.58, marking a 1,378.46% gain and closing at $130.40, ...
3 min readShares of Spruce Biosciences, Inc. ( NASDAQ:SPRB ) are surging Monday after the biotech company shared an important regulatory update about one of its therapy treatments. What To Know: Spruce Biosciences, which produces novel therapies for neurological disorders, said the U.S.
2 min read
